Lutetium Lu-177 Dotatate Flare Reaction

PURPOSE: Lutetium Lu-177 dotatate is the first peptide receptor radionuclide therapy approved by the US Food and Drug Administration. Well-designed studies in Europe have shown dramatic effectiveness in improving progression-free survival in patients with gastroenteropancreatic neuroendocrine tumors...

Full description

Saved in:
Bibliographic Details
Published in:Adv Radiat Oncol
Main Authors: Salner, Andrew L., Blankenship, Bette, Dunnack, Hayley, Niemann, Christopher, Bertsch, Helaine
Format: Artigo
Language:Inglês
Published: Elsevier 2020
Subjects:
Brief Opinion
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7811111/
https://ncbi.nlm.nih.gov/pubmed/33490736
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.adro.2020.11.008
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items